

S Ronconi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7953671/publications.pdf>

Version: 2024-02-01

45
papers

1,396
citations

430442

18
h-index

329751

37
g-index

45
all docs

45
docs citations

45
times ranked

1565
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Patients with multiple myeloma referred for palliative care consultation: from retrospective analysis to future directions to improve clinical outcomes. <i>Supportive Care in Cancer</i> , 2022, 30, 2293-2298. | 1.0 | 6 |
| 2 | CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 2639. | 1.7 | 17 |
| 3 | Microbiological evaluation of environmental cleanliness in haematopoietic cell transplant patient rooms: implementing JACIE standards. <i>Journal of Hospital Infection</i> , 2020, 104, 276-282. | 1.4 | 2 |
| 4 | An 1H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia. <i>Anti-Cancer Drugs</i> , 2020, 31, 67-72. | 0.7 | 1 |
| 5 | Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. <i>Lancet Haematology</i> , 2020, 7, e861-e873. | 2.2 | 34 |
| 6 | Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. <i>Blood Cancer Journal</i> , 2020, 10, 58. | 2.8 | 9 |
| 7 | An immunotherapy-induced plasma cell leukaemoid reaction. <i>British Journal of Haematology</i> , 2020, 188, 813-813. | 1.2 | 2 |
| 8 | Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 395. | 1.0 | 4 |
| 9 | Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma. <i>Blood</i> , 2020, 136, 1-1. | 0.6 | 0 |
| 10 | Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment With Pomalidomide-Dexamethasone. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e358. | 0.2 | 0 |
| 11 | Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. <i>Cancers</i> , 2019, 11, 1735. | 1.7 | 7 |
| 12 | Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pretreated Multiple Myeloma: Old/New in Novel Agents' Era. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e359-e360. | 0.2 | 0 |
| 13 | Maintenance Therapy vs Re-treatment at Biochemical Relapse vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II, Randomized Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e271. | 0.2 | 0 |
| 14 | Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e358-e359. | 0.2 | 0 |
| 15 | Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patients' Characteristics. <i>Blood</i> , 2019, 134, 4357-4357. | 0.6 | 3 |
| 16 | Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITAcA trial. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5261-5268. | 1.0 | 8 |
| 17 | Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study. <i>Blood</i> , 2018, 132, 305-305. | 0.6 | 30 |
| 18 | Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2018, 132, 121-121. | 0.6 | 46 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma. <i>Annals of Hematology</i> , 2017, 96, 2071-2078. | 0.8 | 4 |
| 20 | Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2016, 101, e196-e199. | 1.7 | 15 |
| 21 | IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia. <i>Journal of Translational Medicine</i> , 2015, 13, 229. | 1.8 | 23 |
| 22 | Atypical presentations of thrombotic thrombocytopenic purpura in middle-aged women with recurrent cerebral macrovascular thrombosis: a case report. <i>Annals of Hematology</i> , 2015, 94, 1597-1598. | 0.8 | 2 |
| 23 | Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 673-678. | 1.3 | 21 |
| 24 | Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients. <i>Blood</i> , 2013, 122, 2289-2289. | 0.6 | 0 |
| 25 | Prolonged 18FDG-PET negative complete remission in a heavily pretreated, elderly patient with diffuse large B cell lymphoma treated with lenalidomide, low dose dexamethasone, and colony stimulating factor (Rd-G). <i>American Journal of Hematology</i> , 2011, 86, 79-80. | 2.0 | 5 |
| 26 | Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. <i>Cancer Genetics and Cytogenetics</i> , 2010, 199, 76-80. | 1.0 | 28 |
| 27 | Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). <i>Lancet Oncology</i> , 2008, 9, 352-358. | 5.1 | 80 |
| 28 | R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: A pilot study. <i>Leukemia and Lymphoma</i> , 2008, 49, 1081-1086. | 0.6 | 52 |
| 29 | Osteonecrosis of the Jaw in Patients with Bone Metastases Treated with Bisphosphonates: A Retrospective Study. <i>Oncologist</i> , 2008, 13, 330-336. | 1.9 | 53 |
| 30 | Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 2434-2441. | 0.8 | 329 |
| 31 | Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia. <i>Haematologica</i> , 2007, 92, 564-565. | 1.7 | 25 |
| 32 | R-COMP 21 (Prednisone, Cyclophosphamide, Vincristine, Myocetm and Rituximab) for Frail and Elderly Patients with Aggressive B-Cell Non-Hodgkin Lymphoma: A Pilot Study.. <i>Blood</i> , 2007, 110, 4442-4442. | 0.6 | 0 |
| 33 | Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. <i>Blood</i> , 2006, 108, 3951-3952. | 0.6 | 53 |
| 34 | Secondary Lung Tumors in Hematological Patients. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2005, 26, 520-526. | 0.8 | 12 |
| 35 | A case of primary extramedullary plasmacytoma of the colon. <i>International Journal of Colorectal Disease</i> , 2004, 19, 289-291. | 1.0 | 39 |
| 36 | Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. <i>Leukemia</i> , 2000, 14, 1310-1313. | 3.3 | 70 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. <i>Blood</i> , 2000, 96, 355-357. | 0.6 | 91 |
| 38 | Molecular Remission After Allogeneic or Autologous Transplantation of Hematopoietic Stem Cells for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2000, 18, 2273-2281. | 0.8 | 153 |
| 39 | Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. <i>Blood</i> , 2000, 95, 2234-2239. | 0.6 | 66 |
| 40 | Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. <i>Blood</i> , 2000, 95, 2234-2239. | 0.6 | 2 |
| 41 | Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. <i>Blood</i> , 2000, 96, 355-357. | 0.6 | 1 |
| 42 | Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study. <i>British Journal of Haematology</i> , 1999, 107, 419-428. | 1.2 | 25 |
| 43 | <i>In vitro</i> treatment with retinoids decreases bcl-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells. <i>European Journal of Haematology</i> , 1999, 62, 143-148. | 1.1 | 17 |
| 44 | High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. <i>Bone Marrow Transplantation</i> , 1998, 22, 27-32. | 1.3 | 54 |
| 45 | A system-on-a-programmable-chip for real-time control of massively parallel arrays of biosensors and actuators. , 0, , . | | 7 |